pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-155 |
Genomic Coordinates | chr21: 25573980 - 25574044 |
Description | Homo sapiens miR-155 stem-loop |
Comment | Human mir-155 is predicted based on homology to a cloned miR from mouse (MIR:MI0000177) . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-155-3p | ||||||||||||||||||
Sequence | 43| CUCCUACAUAUUAGCAUUAACA |64 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | DNAJA1 | ||||||||||||||||||||
Synonyms | DJ-2, DjA1, HDJ2, HSDJ, HSJ-2, HSJ2, HSPF4, NEDD7, hDJ-2 | ||||||||||||||||||||
Description | DnaJ heat shock protein family (Hsp40) member A1 | ||||||||||||||||||||
Transcript | NM_001539 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on DNAJA1 | |||||||||||||||||||||
3'UTR of DNAJA1 (miRNA target sites are highlighted) |
>DNAJA1|NM_001539|3'UTR 1 TGGGCCAGTGAATAACACTCACTGCTGGCATTTAATGTGCAGTAGTGAATGAGTGAAGGACTGTAATCATAATATGCTCA 81 CTACTTGCTCTTGTTTTTGTTTTAATAAACTATAGTAGTGTTTTAAAAAGTTAAATGAAGAATAAACGCAAATATAAAAG 161 CTCTGATTTTGCCCTGTATGTATGATGACTTCAGTGTGCAAGATGAAGTTTAATACCTGTAAAAACTACAAAGAAGTTCC 241 CCTAGCATTTCTAGGCCAAACCTTGTAATTGACTTCAGCTATGTACGTGGACAAGCTTAGACTGAAATGCTAGGTATATG 321 TATTGGCTTCAGTGTATGACCCTTCATTGTTAAGCTATGAAAGTAAAACTCTGTATTTAACTGGCAATGAGGAAAAAAAA 401 ATTTTGTAGAGAAGTGTTGGTCTGTATAGTTCTTTATATTAAGTGGGATTCATTGTAATGCCTCTGCATTTATTCTGTTG 481 CCTCAGCTGTTACTTGAAGATGGCGTAATATATAATTTATCCTGTGGTATCAGTGATAAAAATGATACCTTTCTGTAGGA 561 GGGGTTTATCATAATATGCTGCTTCTTGAAGGCTTGCACTTCCAGAATTGTGTTTCCTTCTGCTGTGCCATTCATATATA 641 TATACATATATATATATAATCTTGACCAGTCCTGGTCATTTGCTCCCCTCCTTGTCTGTGGACCATGATAAGCCCAAGTA 721 GTGACTTCAGAGCTGGGTAACAGAAATTAAAGTGAAAAGACCTTTACGTGGAGAATTTGCATGCGTAATATAGGAAGGTG 801 TTCTTTAGGTATGTTACAGGATTACTTTAAACCATTTGACTTTCGCTCCAAAGTTATGTTGGTAGTATAGCAAATTATGA 881 TGAATAGCTTTAATTGTATGTTTAAAAGTCTCATATGTTCACATGCTTAAATCTGGGTATCAGAATTTAAGCAATTCTTG 961 AAATGTATTGTCTCCTTAATATACTAATTACAAAGCATCTCCAAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Disease | 3301.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"HITS-CLIP data was present in GSM714642. RNA binding protein: AGO2. Condition:completeT1
"PAR-CLIP data was present in GSM714644. RNA binding protein: AGO2. Condition:completeT1
"PAR-CLIP data was present in GSM714645. RNA binding protein: AGO2. Condition:completeT1
... - Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods. |
Article |
- Kishore S; Jaskiewicz L; Burger L; Hausser et al. - Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Disease | 3301.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM1065667. RNA binding protein: AGO1. Condition:4-thiouridine
"PAR-CLIP data was present in GSM1065668. RNA binding protein: AGO1. Condition:4-thiouridine
"PAR-CLIP data was present in GSM1065669. RNA binding protein: AGO1. Condition:4-thiouridine
... - Memczak S; Jens M; Elefsinioti A; Torti F; et al., 2013, Nature. |
Article |
- Memczak S; Jens M; Elefsinioti A; Torti F; et al. - Nature, 2013
Circular RNAs (circRNAs) in animals are an enigmatic class of RNA with unknown function. To explore circRNAs systematically, we sequenced and computationally analysed human, mouse and nematode RNA. We detected thousands of well-expressed, stable circRNAs, often showing tissue/developmental-stage-specific expression. Sequence analysis indicated important regulatory functions for circRNAs. We found that a human circRNA, antisense to the cerebellar degeneration-related protein 1 transcript (CDR1as), is densely bound by microRNA (miRNA) effector complexes and harbours 63 conserved binding sites for the ancient miRNA miR-7. Further analyses indicated that CDR1as functions to bind miR-7 in neuronal tissues. Human CDR1as expression in zebrafish impaired midbrain development, similar to knocking down miR-7, suggesting that CDR1as is a miRNA antagonist with a miRNA-binding capacity ten times higher than any other known transcript. Together, our data provide evidence that circRNAs form a large class of post-transcriptional regulators. Numerous circRNAs form by head-to-tail splicing of exons, suggesting previously unrecognized regulatory potential of coding sequences.
LinkOut: [PMID: 23446348]
|
Experimental Support 4 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | MCF7 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated
... - Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology. |
Article |
- Farazi TA; Ten Hoeve JJ; Brown M; et al. - Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
|
CLIP-seq Support 1 for dataset GSM714642 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repA |
Location of target site | ENST00000330899.4 | 3UTR | UAGGAGGGGUUUAUCAUAAUAUGCUGCUUCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000330899.4 | 3UTR | UAGGAGGGGUUUAUCAUAAUAUGCUGCUUCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM714644 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repA |
Location of target site | ENST00000330899.4 | 3UTR | UAGGAGGGGUUUAUCAUAAUAUGCUGCUUCUUGAAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM714645 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repB |
Location of target site | ENST00000330899.4 | 3UTR | UAGGAGGGGUUUAUCAUAAUAUGCUGCUUCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 5 for dataset GSM1065667 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_6 |
Location of target site | ENST00000330899.4 | 3UTR | UGUAGGAGGGGUUUAUCAUAAUAUGCUGCUUCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
CLIP-seq Support 6 for dataset GSM1065668 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_7 |
Location of target site | ENST00000330899.4 | 3UTR | AGGAGGGGUUUAUCAUAAUAUGCUGCUUCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
CLIP-seq Support 7 for dataset GSM1065669 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_8 |
Location of target site | ENST00000330899.4 | 3UTR | UAGGAGGGGUUUAUCAUAAUAUGCUGCUUCUU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
CLIP-seq Support 8 for dataset SRR1045082 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | MCF7 / Untreated |
Location of target site | ENST00000330899.4 | 3UTR | UAGGAGGGGUUUAUCAUAAUAUGCUGCUUCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 24398324 / SRX388831 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
73 hsa-miR-155-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT005808 | IRAK3 | interleukin 1 receptor associated kinase 3 | 4 | 1 | ||||||||
MIRT082844 | ZNF460 | zinc finger protein 460 | 2 | 4 | ||||||||
MIRT256047 | UBE2K | ubiquitin conjugating enzyme E2 K | 2 | 4 | ||||||||
MIRT437787 | PTEN | phosphatase and tensin homolog | 2 | 1 | ||||||||
MIRT456168 | ZDHHC6 | zinc finger DHHC-type containing 6 | 2 | 2 | ||||||||
MIRT464916 | TXNIP | thioredoxin interacting protein | 2 | 4 | ||||||||
MIRT475559 | HNRNPF | heterogeneous nuclear ribonucleoprotein F | 2 | 2 | ||||||||
MIRT499608 | DNAJA1 | DnaJ heat shock protein family (Hsp40) member A1 | 2 | 8 | ||||||||
MIRT504220 | MYO6 | myosin VI | 2 | 4 | ||||||||
MIRT504256 | C1orf147 | chromosome 1 open reading frame 147 | 2 | 4 | ||||||||
MIRT507642 | CREBRF | CREB3 regulatory factor | 2 | 2 | ||||||||
MIRT522858 | KIAA1551 | KIAA1551 | 2 | 2 | ||||||||
MIRT527505 | MYD88 | myeloid differentiation primary response 88 | 5 | 2 | ||||||||
MIRT530713 | ORMDL3 | ORMDL sphingolipid biosynthesis regulator 3 | 2 | 2 | ||||||||
MIRT532851 | ZNF699 | zinc finger protein 699 | 2 | 2 | ||||||||
MIRT535952 | MIA3 | MIA family member 3, ER export factor | 2 | 2 | ||||||||
MIRT539041 | ATXN1L | ataxin 1 like | 2 | 4 | ||||||||
MIRT556391 | LUC7L | LUC7 like | 2 | 2 | ||||||||
MIRT558617 | CNOT6L | CCR4-NOT transcription complex subunit 6 like | 2 | 2 | ||||||||
MIRT559869 | ATXN3 | ataxin 3 | 2 | 2 | ||||||||
MIRT569208 | SHC3 | SHC adaptor protein 3 | 2 | 2 | ||||||||
MIRT573122 | C18orf25 | chromosome 18 open reading frame 25 | 2 | 2 | ||||||||
MIRT575076 | Ddit4 | DNA-damage-inducible transcript 4 | 2 | 2 | ||||||||
MIRT607597 | ABCF3 | ATP binding cassette subfamily F member 3 | 2 | 6 | ||||||||
MIRT609386 | PHEX | phosphate regulating endopeptidase homolog X-linked | 2 | 2 | ||||||||
MIRT610550 | MDN1 | midasin AAA ATPase 1 | 2 | 2 | ||||||||
MIRT612390 | TCF7L2 | transcription factor 7 like 2 | 2 | 2 | ||||||||
MIRT612910 | GTDC1 | glycosyltransferase like domain containing 1 | 2 | 6 | ||||||||
MIRT613314 | ARL5C | ADP ribosylation factor like GTPase 5C | 2 | 2 | ||||||||
MIRT613356 | ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif 5 | 2 | 4 | ||||||||
MIRT613541 | CLMP | CXADR like membrane protein | 2 | 2 | ||||||||
MIRT617029 | SYT6 | synaptotagmin 6 | 2 | 2 | ||||||||
MIRT618044 | MRVI1 | murine retrovirus integration site 1 homolog | 2 | 2 | ||||||||
MIRT619307 | KIRREL | kirre like nephrin family adhesion molecule 1 | 2 | 2 | ||||||||
MIRT623209 | MTFR1L | mitochondrial fission regulator 1 like | 2 | 2 | ||||||||
MIRT625448 | RANGAP1 | Ran GTPase activating protein 1 | 2 | 2 | ||||||||
MIRT634551 | MACC1 | MACC1, MET transcriptional regulator | 2 | 2 | ||||||||
MIRT640740 | EPB41 | erythrocyte membrane protein band 4.1 | 2 | 2 | ||||||||
MIRT640906 | RAB13 | RAB13, member RAS oncogene family | 2 | 2 | ||||||||
MIRT644025 | ZNF792 | zinc finger protein 792 | 2 | 2 | ||||||||
MIRT651489 | WT1 | Wilms tumor 1 | 2 | 2 | ||||||||
MIRT652037 | LINC00598 | long intergenic non-protein coding RNA 598 | 2 | 2 | ||||||||
MIRT669093 | CDK6 | cyclin dependent kinase 6 | 2 | 2 | ||||||||
MIRT696720 | WNT3 | Wnt family member 3 | 2 | 2 | ||||||||
MIRT698085 | TPM1 | tropomyosin 1 | 2 | 2 | ||||||||
MIRT703284 | GID4 | GID complex subunit 4 homolog | 2 | 2 | ||||||||
MIRT707183 | ARHGEF33 | Rho guanine nucleotide exchange factor 33 | 2 | 2 | ||||||||
MIRT710362 | CREB5 | cAMP responsive element binding protein 5 | 2 | 2 | ||||||||
MIRT713501 | DCAF17 | DDB1 and CUL4 associated factor 17 | 2 | 2 | ||||||||
MIRT717153 | LRRC3C | leucine rich repeat containing 3C | 2 | 2 | ||||||||
MIRT719038 | ATP1A1 | ATPase Na+/K+ transporting subunit alpha 1 | 2 | 2 | ||||||||
MIRT719489 | LSG1 | large 60S subunit nuclear export GTPase 1 | 2 | 2 | ||||||||
MIRT720284 | DPYSL3 | dihydropyrimidinase like 3 | 2 | 2 | ||||||||
MIRT732474 | NLRP3 | NLR family pyrin domain containing 3 | 2 | 0 | ||||||||
MIRT732620 | MS | multiple sclerosis | 1 | 0 | ||||||||
MIRT732968 | TGFBR2 | transforming growth factor beta receptor 2 | 3 | 0 | ||||||||
MIRT733063 | AGTR1 | angiotensin II receptor type 1 | 3 | 0 | ||||||||
MIRT733206 | ADAM10 | ADAM metallopeptidase domain 10 | 1 | 0 | ||||||||
MIRT733302 | CRP | C-reactive protein | 2 | 0 | ||||||||
MIRT734202 | PDCD4 | programmed cell death 4 | 3 | 0 | ||||||||
MIRT734467 | SIRT1 | sirtuin 1 | 2 | 0 | ||||||||
MIRT734701 | Foxo3 | forkhead box O3 | 1 | 0 | ||||||||
MIRT734889 | SP4 | Sp4 transcription factor | 2 | 0 | ||||||||
MIRT735047 | BATF | basic leucine zipper ATF-like transcription factor | 1 | 0 | ||||||||
MIRT735048 | SPI1 | Spi-1 proto-oncogene | 1 | 0 | ||||||||
MIRT735734 | PICALM | phosphatidylinositol binding clathrin assembly protein | 3 | 0 | ||||||||
MIRT735944 | TNF | tumor necrosis factor | 1 | 0 | ||||||||
MIRT736131 | MYLK | myosin light chain kinase | 2 | 0 | ||||||||
MIRT736780 | FOXP3 | forkhead box P3 | 1 | 0 | ||||||||
MIRT736781 | CEBPB | CCAAT/enhancer binding protein beta | 1 | 0 | ||||||||
MIRT736858 | WEE1 | WEE1 G2 checkpoint kinase | 2 | 0 | ||||||||
MIRT736873 | TLR3 | toll like receptor 3 | 2 | 0 | ||||||||
MIRT736902 | CFH | complement factor H | 2 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|